- Home
- CDTX vs BATRK Comparison
CDTX vs BATRK Comparison
Compare CDTX & BATRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CDTX
- BATRK
- Stock Information
- Founded
- CDTX 2012
- BATRK 1991
- Country
- CDTX United States
- BATRK United States
- Employees
- CDTX N/A
- BATRK N/A
- Industry
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- BATRK Broadcasting
- Sector
- CDTX Health Care
- BATRK Industrials
- Exchange
- CDTX Nasdaq
- BATRK Nasdaq
- Market Cap
- CDTX 2.8B
- BATRK 2.5B
- IPO Year
- CDTX 2015
- BATRK N/A
- Fundamental
- Price
- CDTX $219.75
- BATRK $38.45
- Analyst Decision
- CDTX Buy
- BATRK Strong Buy
- Analyst Count
- CDTX 13
- BATRK 3
- Target Price
- CDTX $119.44
- BATRK $58.00
- AVG Volume (30 Days)
- CDTX 2.2M
- BATRK 339.3K
- Earning Date
- CDTX 11-06-2025
- BATRK 11-05-2025
- Dividend Yield
- CDTX N/A
- BATRK N/A
- EPS Growth
- CDTX N/A
- BATRK N/A
- EPS
- CDTX N/A
- BATRK N/A
- Revenue
- CDTX N/A
- BATRK $723,307,000.00
- Revenue This Year
- CDTX N/A
- BATRK N/A
- Revenue Next Year
- CDTX N/A
- BATRK N/A
- P/E Ratio
- CDTX N/A
- BATRK N/A
- Revenue Growth
- CDTX N/A
- BATRK 6.62
- 52 Week Low
- CDTX $15.02
- BATRK $35.46
- 52 Week High
- CDTX $220.32
- BATRK $47.18
- Technical
- Relative Strength Index (RSI)
- CDTX 89.35
- BATRK 38.95
- Support Level
- CDTX $102.46
- BATRK $38.29
- Resistance Level
- CDTX $218.85
- BATRK $39.64
- Average True Range (ATR)
- CDTX 4.30
- BATRK 0.86
- MACD
- CDTX 12.80
- BATRK -0.07
- Stochastic Oscillator
- CDTX 99.47
- BATRK 16.41
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.
About BATRK Atlanta Braves Holdings Inc. Series C
Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include: Baseball which generates key revenue, and Mixed-Use Development.